Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.72 |
| ▸ | CTSK | P43235 | 11/20 | 0.70 |
| ▸ | CTSS | P25774 | 3/20 | 0.67 |
| ▸ | CTSB | P07858 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3682305 | 0.90 | CTSK (0.77) | CTSLCTSKCTSSCTSB | |
| SCHEMBL3681981 | 0.89 | CTSK (0.67) | CTSLCTSKCTSSCTSB | |
| SCHEMBL8236603 | 0.88 | CTSL (0.54) | CTSLCTSKCTSSCTSB | |
| SCHEMBL5384933 | 0.88 | CTSL (0.82) | CTSLCTSKCTSSCTSB | |
| SCHEMBL3674824 | 0.87 | CTSK (0.72) | CTSLCTSKCTSSCTSB | |
| SCHEMBL2156165 | 0.84 | CTSL (1.00) | CTSLCTSKCTSSCTSB | |
| SCHEMBL2157209 | 0.83 | CTSK (0.87) | CTSLCTSKCTSSCTSB | |
| SCHEMBL3681083 | 0.83 | CTSK (0.80) | CTSLCTSKCTSSCTSB | |
| Bicarbonate SCHEMBL15752090 | 0.82 | CTSL (0.81) | CTSLCTSKCTSSCTSB | |
| SCHEMBL3678835 | 0.82 | CTSK (0.80) | CTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694647-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2016-11-09 | — | — | EP | claimed |
| US-7687524-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2010-03-30 | — | — | US | claimed |
| US-20090264479-A1 | Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases | MERCK FROSST CANADA LTD. (CA) | 2009-10-22 | — | — | US | claimed |
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-05-03 | — | — | US | claimed |
| EP-1694647-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2016-11-09 | — | — | EP | disclosed |
| US-7687524-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2010-03-30 | — | — | US | disclosed |
| US-20090264479-A1 | Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases | MERCK FROSST CANADA LTD. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264479-A1 | Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases | MERCK FROSST CANADA LTD. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264479-A1 | Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases | MERCK FROSST CANADA LTD. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264479-A1 | Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases | CTSL, CSTB, PREP | CTSL 1/4885CTSK 54/4885CTSS 11/4885 |
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSL 8/4885CTSK 4/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.